ARYX — Aryx Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Aryx Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2005 December 31st	2006 December 31st	2007 December 31st	C2008 December 31st	2009 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	4.74	4.16	19.7	0
Cost of Revenue
Gross Profit	0	2.62	3.9	19.5	0
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	28.2	33	33	50.1	31.2
Operating Profit	-28.2	-28.3	-28.8	-30.4	-31.2
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-28	-27.3	-27.6	-31.2	-33.2
Provision for Income Taxes
Net Income After Taxes	-28	-27.3	-27.6	-31.2	-33.2
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-28	-27.3	-27.6	-31.2	-33.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-28	-27.3	-27.6	-31.2	-33.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.59	-1.56	-1.56	-1.65	-1.2
Dividends per Share